Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury
Acta Neuropathologica · 2024-06 · 147 (1)
DOI: 10.1007/s00401-024-02758-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 22.06.2024. Verfasst von Fari Ryan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research in Neuroscience, The BRAiN Program, The Research Institute of the McGill University Health Centre, Livingston Hall, Room L7-210, …. Hauptthemen laut MEDLINE: Ferroptosis, Spinal Cord Injuries. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Wings for Life, CIHR.
Abstract (Originalsprache)
We show that redox active iron can induce a regulated form of non-apoptotic cell death and tissue damage called ferroptosis that can contribute to secondary damage and functional loss in the acute and chronic periods after spinal cord injury (SCI) in young, adult, female mice. Phagocytosis of red blood cells at sites of hemorrhage is the main source of iron derived from hemoglobin after SCI. Expression of hemeoxygenase-1 that induces release of iron from heme, is increased in spinal cord macrophages 7 days after injury. While iron is stored safely in ferritin in the injured spinal cord, it can, however, be released by NCOA4-mediated shuttling of ferritin to autophagosomes for degradation (ferritinophagy). This leads to the release of redox active iron that can cause free radical damage. Expression of NCOA4 is increased after SCI, mainly in macrophages. Increase in the ratio of redox active ferrous (Fe 2+ ) to ferric iron (Fe 3+ ) is also detected after SCI by capillary electrophoresis inductively coupled mass spectrometry. These changes are accompanied by other hallmarks of ferroptosis, i.e., deficiency in various elements of the antioxidant glutathione (GSH) pathway. We also detect increases in enzymes that repair membrane lipids (ACSL4 and LPCAT3) and thus promote on-going ferroptosis. These changes are associated with increased levels of 4-hydroxynonenal (4-HNE), a toxic lipid peroxidation product. Mice with mild SCI (30 kdyne force) treated with the ferroptosis inhibitor (UAMC-3203-HCL) either early or delayed times after injury showed improvement in locomotor recovery and secondary damage. Cerebrospinal fluid and serum samples from human SCI cases show evidence of increased iron storage (ferritin), and other iron related molecules, and reduction in GSH. Collectively, these data suggest that ferroptosis contributes to secondary damage after SCI and highlights the possible use of ferroptosis inhibitors to treat SCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Research in Neuroscience, The BRAiN Program, The Research Institute of the McGill University Health Centre, Livingston Hall, Room L7-210, 1650 Cedar Ave., Montreal, QC, H3G 1A4, Canada.
- Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Research Unit Analytical BioGeoChemistry, Helmholz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080, Würzburg, Germany.
- Belford Center for Spinal Cord Injury and Departments of Neurology and Neurosciences, The Ohio State University, Columbus, OH, 43210, USA.
- Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Samuel David
Förderung
- Deutsche Forschungsgemeinschaft
- Wings for Life
- CIHR
- Else Kröner-Fresenius-Stiftung
- NINDS NIH HHS
- Canadian Institutes of Health Research
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Ryan, F., Blex, C., Ngo, T. D., Kopp, M. A., Michalke, B., Venkataramani, V., Curran, L., Schwab, J. M., Ruprecht, K., Otto, C., Jhelum, P., Kroner, A., & David, S. (2024). Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02758-2
Vancouver
Ryan F, Blex C, Ngo TD, Kopp MA, Michalke B, Venkataramani V, et al. Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury. Acta Neuropathologica. 2024;147(1). doi:10.1007/s00401-024-02758-2
BibTeX
@article{Ryan2024,
author = {Ryan, Fari and Blex, Christian and Ngo, The Dung and Kopp, Marcel A and Michalke, Bernhard and Venkataramani, Vivek and Curran, Laura and Schwab, Jan M and Ruprecht, Klemens and Otto, Carolin and Jhelum, Priya and Kroner, Antje and David, Samuel},
title = {Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury},
journal = {Acta Neuropathologica},
year = {2024},
volume = {147},
number = {1},
doi = {10.1007/s00401-024-02758-2}
}
EUVIMED